Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
NCT ID: NCT00731224
Last Updated: 2017-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
380 participants
INTERVENTIONAL
2008-07-31
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
NCT00099242
Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
NCT00561392
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
NCT00423085
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
NCT00219232
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
NCT01399125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Rivastigmine transdermal patch
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rivastigmine transdermal patch
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* MMSE score of ≥10 and ≤ 26;
Exclusion Criteria
* Body weight less than 40 kg;
* Hypersensitivity to cholinesterase inhibitors.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
East Gosford, New South Wales, Australia
Novartis Investigative Site
Gosford, New South Wales, Australia
Novartis Investigative Site
Hornsby, New South Wales, Australia
Novartis Investigative Site
Randwick, New South Wales, Australia
Novartis Investigative Site
Chemside, Queensland, Australia
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Woodville, South Australia, Australia
Novartis Investigative Site
Ballarat, Victoria, Australia
Novartis Investigative Site
Fitzroy, Victoria, Australia
Novartis Investigative Site
Heidelberg, Victoria, Australia
Novartis Investigative Site
Nedlands, , Australia
Novartis Investigative Site
Johor Bahru, Johor, Malaysia
Novartis Investigative Site
Seremban, Negeri Sembilan, Malaysia
Novartis Investigative Site
Ipoh, Perak, Malaysia
Novartis Investigative Site
Kuala Lumpur, Selangor, Malaysia
Novartis Investigative Site
Kuala Lumpur, , Malaysia
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Bundang, Seongnam, South Korea
Novartis Investigative Site
Seoul, , South Korea
Novartis Investigative Site
Bangkok, , Thailand
Novartis Investigative Site
Bangkok, , Thailand
Novartis Investigative Site
Bangkok, , Thailand
Novartis Investigative Site
Ankara, Turkey, Turkey (Türkiye)
Novartis Investigative Site
Ankara, Turkey, Turkey (Türkiye)
Novartis Investigative Site
Bursa, Turkey, Turkey (Türkiye)
Novartis Investigative Site
Izmir, Turkey, Turkey (Türkiye)
Novartis Investigative Site
Konya, Turkey, Turkey (Türkiye)
Novartis Investigative Site
Altunizade, , Turkey (Türkiye)
Novartis Investigative Site
Antalya, , Turkey (Türkiye)
Novartis Investigative Site
Atakum / Samsun, , Turkey (Türkiye)
Novartis Investigative Site
Emek / Ankara, , Turkey (Türkiye)
Novartis Investigative Site
Etlik / Ankara, , Turkey (Türkiye)
Novartis Investigative Site
Istanbul, , Turkey (Türkiye)
Novartis Investigative Site
Istanbul, , Turkey (Türkiye)
Novartis Investigative Site
Izmir, , Turkey (Türkiye)
Novartis Investigative Site
Kocaeli, , Turkey (Türkiye)
Novartis Investigative Site
Mersin, , Turkey (Türkiye)
Novartis Investigative Site
Meselik / Eskisehir, , Turkey (Türkiye)
Novartis Investigative Site
Talas / Kayseri, , Turkey (Türkiye)
Novartis Investigative Site
Uskudar / Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CENA713DAU01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.